Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Total Liabilities: 2010-2025

Historic Total Liabilities for Ligand Pharmaceuticals (LGND) over the last 15 years, with Sep 2025 value amounting to $526.6 million.

  • Ligand Pharmaceuticals' Total Liabilities rose 363.20% to $526.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $526.6 million, marking a year-over-year increase of 363.20%. This contributed to the annual value of $111.3 million for FY2024, which is 29.00% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Total Liabilities stood at $526.6 million for Q3 2025, which was up 338.56% from $120.1 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Total Liabilities ranged from a high of $549.3 million in Q1 2021 and a low of $86.3 million during Q4 2023.
  • Moreover, its 3-year median value for Total Liabilities was $109.9 million (2025), whereas its average is $147.8 million.
  • In the last 5 years, Ligand Pharmaceuticals' Total Liabilities plummeted by 65.97% in 2023 and then skyrocketed by 363.20% in 2025.
  • Quarterly analysis of 5 years shows Ligand Pharmaceuticals' Total Liabilities stood at $476.4 million in 2021, then crashed by 65.33% to $165.2 million in 2022, then tumbled by 47.75% to $86.3 million in 2023, then increased by 29.00% to $111.3 million in 2024, then spiked by 363.20% to $526.6 million in 2025.
  • Its Total Liabilities was $526.6 million in Q3 2025, compared to $120.1 million in Q2 2025 and $109.9 million in Q1 2025.